CLINICAL TRIALS PROFILE FOR VABICASERIN
✉ Email this page to a colleague
Clinical Trials for Vabicaserin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00541996 ↗ | Study Comparing Bioavailability of Oral Formulations of Vabicaserin | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin. |
NCT00563706 ↗ | Study Evaluating Vabicaserin in Subjects With Schizophrenia | Completed | Pfizer | Phase 2 | The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia. |
NCT00768612 ↗ | Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 | This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone. |
NCT00928551 ↗ | Comparative Formulation Study of Vabicaserin | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | This study will compare two different formulations of vabicaserin. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Vabicaserin
Condition Name
Clinical Trial Locations for Vabicaserin
Trials by Country
Clinical Trial Progress for Vabicaserin
Clinical Trial Phase
Clinical Trial Sponsors for Vabicaserin
Sponsor Name